Management of indolent lymphoma: Where are we now and where are we going

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalBlood Reviews
Volume26
Issue number6
DOIs
StatePublished - Nov 2012

Keywords

  • Bendamustine
  • Bortezomib
  • Bruton's tyrosine kinase
  • CD20
  • Cyclophosphamide
  • Doxorubicin
  • Fludarabine
  • Follicular
  • Histone deacetylase inhibitors
  • Indolent lymphoma
  • Lenalidomide
  • MTOR
  • Marginal zone
  • Non-Hodgkin
  • PI3K
  • Rituximab
  • Small lymphocytic

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Management of indolent lymphoma: Where are we now and where are we going'. Together they form a unique fingerprint.

Cite this